Seipasa is a leading company specialized in natural treatments for agriculture. Seipasa is pioneer in researching, manufacturing and marketing biopesticides, biostimulants and fertilizers. The company has been working for 20 years in natural protection of crops and plant biostimulation based on solutions of botanical origin. From its headquarters in Valencia, Spain, and conducted by the R&D department, the company formulates and certificates solutions of high technological value which are applied in the most demanding agricultures of the world. Seipasa is stablished in over 20 countries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

news image

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More

DIAGNOSTICS

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

news image

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

MEDTECH

OUTCOMES4ME PARTNERS WITH INVITAE TO OFFER GENETIC TESTING TO BREAST CANCER PATIENTS

Outcomes4Me | October 12, 2021

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me’s 360-degree, validated and evidence-based cancer support and tr...

Read More
news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

DIAGNOSTICS

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More